PDL BioPharma (PDLI) Misses Q4 EPS by 25c

PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.32, $0.25 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $117.1 million versus the consensus estimate of $158.15 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Norwegian Cruise Line rating cut at Mizuho after 'self-inflicted wounds'
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• Goldman Sachs updates view on protein markets ahead of earnings